Once only for making us look younger, the clinical value of Botox continues to grow.  Also see another recent FDA approval for Cervical dystonia below.  The botox shots are for those who have chronic headaches and not an occasional situation.  image

FDA Approves Xeomin® A Botulinum Toxin Type A (Botox)To Treat Cervical Dystonia

A visit every 12 weeks for injections is the treatment plan so it looks like 3 months is the amount of time before the next visit to the doctor is due.  Botox has been approved in Europe for migraines since July and there’s even clinical trials in place for topical Botox so perhaps even the shots maybe be a thing of the past one day.  BD

SILVER SPRING, Md., Oct. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.

"Chronic migraine is one of the most disabling forms of headache," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work, and social life, so it is important to have a variety of effective treatment options available."

Migraine usually begins with intermittent headache attacks 14 days or fewer each month (episodic migraine), but some patients go on to develop the more disabling chronic migraine.

To treat chronic migraines, Botox is given approximately every 12 weeks as multiple injections around the head and neck to try to dull future headache symptoms. Botox has not been shown to work for the treatment of migraine headaches that occur 14 days or less per month, or for other forms of headache. It is important that patients discuss with their physician whether Botox is appropriate for them.

FDA Approves Botox to Treat Chronic Migraine -- SILVER SPRING, Md., Oct. 15 /PRNewswire-USNewswire/ --


Post a Comment

Google Analytics Alternative